Abstract:Background and objectives: Spinal muscular atrophy (SMA) is an autosomal recessive disorder caused by biallelic variants of the Survival Motor Neuron 1 gene (SMN1) that affects approximately 1 in 15,000 live births. Availability of 3 SMN-enhancing treatments for SMA has led to urgency to review how clinicians and patients use these treatments for SMA, while additional research and real-world data and experience are being collected. This work describes important factors to assist with decision-making for SMN-enhancing treatments. Methods: A systematic literature review was conducted on SMN-enhancing treatments for SMA and related studies. A working group of American and European health care providers with expertise in SMA care identified barriers and developed recommendations through a modified Delphi technique with serial surveys and feedback through virtual meetings to fill gaps for information where evidence is limited. A community working group of an individual living with SMA and caregivers provided insight and perspective on SMA treatments and support through a virtual meeting to guide recommendations. Results: The health care provider working group and the community working group agreed that when determining whether to start, change, add, or discontinue a treatment, essential considerations include patient and family/caregiver perspective, and treatment safety and side effects. When initiating treatment for patients newly diagnosed with SMA, important patient characteristics are age and Survival Motor Neuron 2 gene (SMN2) copy number. Furthermore, when initiating, changing, or adding treatment, current clinical status and comorbidities drive decision-making. When considering a medication or treatment plan change, unless there is an urgent indication, a treatment and associated patient outcomes should be monitored for a minimum of 6-12 months. When determining a treatment plan with an adolescent or adult with SMA, consider factors such as quality of life, burden vs benefit of treatment, and reproductive issues. Access to care coordination and interdisciplinary/multidisciplinary care are essential to treatment success. Discussion: Sharing information about current knowledge of treatments and shared decision-making between health care providers and patients living with SMA and caregivers are essential to overcoming barriers to providing SMN-enhancing treatments.

Lifesaving Treatments for Spinal Muscular Atrophy: Global Access and Availability (P5-4.003)

Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability

Lifesaving Treatments for Spinal Muscular Atrophy: Global Access and Availability

Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy

Clinicogenetic characterization and response to disease-modifying therapies in spinal muscular atrophy: real-world experience from a reference center in Southern Brazil

Spinal Muscular Atrophy Update in Best Practices: Recommendations for Treatment Considerations

Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians

Advances and limitations for the treatment of spinal muscular atrophy

Recent Advance in Disease Modifying Therapies for Spinal Muscular Atrophy

Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments

Challenges and opportunities in spinal muscular atrophy therapeutics

Spinal muscular atrophy in an upper-middle-income nation before the advent of reimbursed disease-modifying therapies

Diving into progress: a review on current therapeutic advancements in spinal muscular atrophy

Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges

Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies

Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy

Outcomes of early‐treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study

In Search of Spinal Muscular Atrophy Disease Modifiers

Treatment preferences in spinal muscular atrophy: A swing weighting study for caregivers of patients with SMA types 1 and 2

New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?

Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy